Novo Nordisk A/S (NYSE:NVO) Stock Sale Reported by Rep. Kevin Hern

29 Sep 2026, 11:03 by Amy Steele · The Cerbat Gem

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on September 10th. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Novo Nordisk A/S Stock Performance

Shares of NVO traded down $0.57 during mid-day trading on Tuesday, hitting $38.13. 2,577,198 shares of the company’s stock were exchanged, compared to its average volume of 17,068,873. The firm has a market capitalization of $170.27 billion, a P/E ratio of 9.34, a P/E/G ratio of 1.27 and a beta of 0.74. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The business’s 50 day moving average is $45.51 and its two-hundred day moving average is $43.87. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. The company had revenue of $11.98 billion during the quarter. On average, equities analysts expect that Novo Nordisk A/S will post 3.54 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were given a $0.5786 dividend. This is a negative change from Novo Nordisk A/S’s previous dividend of $1.2751. The ex-dividend date was Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s payout ratio is currently 20.05%.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors have recently added to or reduced their stakes in NVO. CoreCap Advisors LLC lifted its position in shares of Novo Nordisk A/S by 4.7% during the 2nd quarter. CoreCap Advisors LLC now owns 5,341 shares of the company’s stock worth $256,000 after purchasing an additional 242 shares during the last quarter. Carson Advisory Inc. grew its holdings in Novo Nordisk A/S by 2.2% in the 1st quarter. Carson Advisory Inc. now owns 12,316 shares of the company’s stock valued at $453,000 after buying an additional 268 shares during the last quarter. Bradley Foster & Sargent Inc. CT increased its position in Novo Nordisk A/S by 0.6% in the 1st quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company’s stock worth $1,726,000 after buying an additional 272 shares during the period. Arlington Partners LLC increased its position in Novo Nordisk A/S by 4.4% in the 2nd quarter. Arlington Partners LLC now owns 6,777 shares of the company’s stock worth $325,000 after buying an additional 283 shares during the period. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of Novo Nordisk A/S by 13.1% during the second quarter. Parkside Financial Bank & Trust now owns 2,436 shares of the company’s stock worth $117,000 after buying an additional 283 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Thursday, September 10th. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Berenberg Bank set a $47.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, August 12th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Three analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus price target of $64.94.

Check Out Our Latest Stock Analysis on NVO

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: Novo reported real-world evidence that patients with type 2 diabetes who increased Ozempic (semaglutide) to 2 mg had a 6% lower risk of major cardiovascular events than patients who switched to Eli Lilly’s Mounjaro (tirzepatide). The findings strengthen Ozempic’s clinical and commercial positioning, although the analysis was retrospective and observational. Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly’s Mounjaro
Positive Sentiment: Novo licensed global rights to HRS-1596, a phase 1-ready once-weekly oral GLP-1/GIP drug from China’s Hengrui Pharmaceuticals. The deal could reach $2.6 billion, including a $300 million upfront payment and royalties, giving Novo another potential oral obesity and diabetes treatment. However, the asset remains at an early development stage. China’s Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
Positive Sentiment: Phase 3 REIMAGINE 5 data showed the lower-dose CagriSema combination produced substantial weight loss in adults with type 2 diabetes, supporting hopes that the candidate can improve Novo’s competitive position against Lilly’s tirzepatide franchise. Novo Nordisk Just Beat Lilly in a Trial
Neutral Sentiment: Novo is also pursuing longer-acting delivery technology through a collaboration with Nanexa, potentially enabling monthly dosing across obesity, diabetes and related indications. The opportunity could support future growth, but development and regulatory uncertainty remain significant. Novo Nordisk Licenses Nanexa’s PharmaShell
Positive Sentiment: Novo continues its share-repurchase program, part of a broader plan to buy back up to DKK 15 billion over 12 months. Buybacks can support earnings per share and signal management confidence in the valuation. Novo Nordisk share repurchase programme
Negative Sentiment: Eli Lilly countered with analysis claiming its oral obesity drug Foundayo delivered greater weight loss and better blood-sugar control than higher-dose Ozempic tablets. The comparison relies on existing, non-head-to-head studies, but it reinforces investor concerns about intensifying competition in oral GLP-1 treatments. Lilly touts Foundayo advantage over Novo’s Ozempic pill

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Novo Nordisk A/S

(Get Free Report)

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.